The methodology can be employed to explore subtle changes in ApoA-I levels as a potential biomarker of cardiovascular disease and as a biological response indicator for tobacco smoking to complement the use of urinary nicotine metabolites. The gene discussed is APOA1; the disease is cardiovascular disorder.